Disposition of Artesunate and Dihydroartemisinin after Administration of Artesunate Suppositories in Children from Papua New Guinea with Uncomplicated Malaria
Open Access
- 1 August 2004
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (8) , 2966-2972
- https://doi.org/10.1128/aac.48.8.2966-2972.2004
Abstract
A detailed pharmacokinetic analysis was performed with 47 children from Papua New Guinea with uncomplicated falciparum or vivax malaria treated with artesunate (ARTS) suppositories (Rectocaps) given in two doses of approximately 13 mg/kg of body weight 12 h apart. Following an intensive sampling protocol, samples were assayed for ARTS and its primary active metabolite, dihydroartemisinin (DHA), by liquid chromatography-mass spectrometry. A population pharmacokinetic model was developed to describe the data. Following administration of the first dose, the mean maximal concentrations of ARTS and DHA were 1,085 nmol/liter at 0.9 h and 2,525 nmol/liter at 2.3 h, respectively. The absorption half-life for ARTS was 2.3 h, and the conversion half-life (ARTS to DHA) was 0.27 h, while the elimination half-life of DHA was 0.71 h. The mean common volumes of distribution for ARTS and DHA relative to bioavailability were 42.8 and 2.04 liters/kg, respectively, and the mean clearance values relative to bioavailability were 6 and 2.2 liters/h/kg for ARTS and DHA, respectively. Substantial interpatient variability was observed, and the bioavailability of the second dose relative to that of the first was estimated to be 0.72. The covariates age, sex, and α-thalassemia genotype were not influential in the pharmacokinetic model development; but the inclusion of weight as a covariate significantly improved the performance of the model. An ARTS suppositories dose of 10 of 20 mg/kg is appropriate for use in children with uncomplicated malaria.Keywords
This publication has 40 references indexed in Scilit:
- Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001The Lancet, 2003
- Safety evaluations of drugs containing artemisinin derivatives for the treatment of malaria.Clinical Infectious Diseases, 2003
- Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New GuineaThe Pediatric Infectious Disease Journal, 2003
- Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto‐induction in the rat by use of nonlinear mixed effects modellingBiopharmaceutics & Drug Disposition, 2003
- Oral Artesunate Dose-Response Relationship in Acute Falciparum MalariaAntimicrobial Agents and Chemotherapy, 2002
- Multiple dose study of interactions between artesunate and artemisinin in healthy volunteersBritish Journal of Clinical Pharmacology, 2001
- Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum MalariaAntimicrobial Agents and Chemotherapy, 2001
- Severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Artemisinin derivatives for treating uncomplicated malariaCochrane Database of Systematic Reviews, 1999
- Metabolism of antimalarial sesquiterpene lactonesPharmacology & Therapeutics, 1990